North America Hair Loss Treatment Products Market

North America Hair Loss Treatment Products Market Size (2024 to 2029)

The North America Hair Loss Treatment Products Market is expected to grow at a whopping CAGR of 3.63% from 2024 to 2029 and be worth USD 0.84 billion by 2029 from USD 0.7 billion in 2024.

One of the major driving factors that help the growth of the North America Hair Loss Treatment Products Market is the changing fashion trends and rise in awareness of the availability of new, more effective, and safer hair loss products across the region, especially in the nations like the United States and Mexico. Increasing expenditure on hair care products in those nations is also one of the driving factors of the North America Hair Loss treatment products market.

Another prominent supporting aspect of North America Hair Loss Treatment Products is the increasing investments by the major players, along with the rising inclination towards origin-specific ingredients across the area.

Impact of COVID-19 North America Hair Loss Treatments Products Market:

The Coronavirus pandemic has affected the business in various ways such as directly impacting production, creating supply chain disturbance, and financial losses. This pandemic has impacted financially in every sector like restaurants, manufacturing units, flights, traveling and so many sectors to halt their services.

Due to COVID-19, North America Hair Loss Treatment Products Market is also facing difficulties and witnessed huge financial losses as the manufacturing industries were stopped due to the financial crisis they faced. As per the analysis, experts from the industry are predicting that the market will record a surge in the coming years and will be back to the normal stage once the vaccine gets released. The governments in several nations have already lifted the lockdown and given permission for the companies to start their businesses under strict rules and regulations.

Increasing concerns among people regarding hair loss across the area, especially among females are one of the major driving factors that helps the North American market to grow further during the conjecture period of 2022 - 2027. As per the report, the market of hair loss treatments products is estimated to increase much further owing to increasing sales, especially in some of the countries such as the United States and Mexico, which in turn will be helpful to increase the revenue rate in the North American marketplace in the upcoming years.

REPORT COVERAGE:

This research report on the North America hair loss treatment market has been segmented and sub-segmented into the following categories.

North America Hair Loss Treatment Products Market – By disease type:

• Alopecia Areata
• Cicatricial Alopecia
• Traction Alopecia
• Alopecia Totalis
• Alopecia Universalis
• Androgenetic Alopecia
• Others

North America Hair Loss Treatment Products Market - By sales channel:

The market of North America Hair Loss Treatment Products Market is divided into over-the-counter (OTC) and prescription-based. Among these, the OTC segment holds the major share of the market due to the increasing number of customers that are buying the products through various offline distribution channels in countries such as the United States and Canada.

North America Hair Loss Treatment Products Market - By End-Use:

• Homecare settings
• Dermatology clinics
• Others.

North America Hair Loss Treatment Products Market – By Region: 

The United States of America

• Canada  
• Mexico

North America region is expected to register an increase in the market share of Hair Loss treatment products owing to increased hair loss due to changing lifestyles and exposure to the environment, growing popularity of brands across the region, especially in various countries such as the United States, Mexico, and Canada in the next few years.

KEY MARKET PLAYERS:

The major key market players in the North America hair Loss Treatments Product Market are Aclaris Therapeutics, Inc, Sun Pharmaceutical Industries Ltd, Concert Pharmaceuticals, Hcell Inc, Histogen Inc, Merck & Co., Inc., Johnson & Johnson Services, Inc., Glaxo Smith Kline Plc